| 摘要 |
This invention provides a purified endotoxin-induced thrombosis factor, preferably an endotoxin-induced thrombosis factor characterized by an apparent molecular weight between about 50,000 and 65,000 daltons, more specifically about 55,000 daltons, on reduced and nonreduced SDS-polyacrylamide gels, by maximal recovery on elution from such gels at 52,000 to 58,000 daltons, by the ability to migrate as a single band on such gels, by the ability to precipitate in ammonium sulfate at saturations from 40% to 70%, by the ability to precipitate in polyethylene glycol at concentrations above 15%, by high hydrophobicity, by the ability to bind weakly to a hydroxylapatite column and to a lentil lectin column, by the ability to bind tightly to a hydrophobic interaction resin and smear off with ethylene glycol, and by the ability to bind tightly to a reverse-phase column and elute more effectively with isopropranol than with acetonitrile, by the ability to bind to an anion exchange resin over a pH range from 5 to 10, by the inability to bind to a cation exchange resin, by resistance to acid denaturation up to 30 minutes, resistance to polymyxin, sensitivity to heating at 95 DEG C. for 30 minutes, and sensitivity to trypsin exposure for 24 hours. Another characteristic of a purified endotoxin-induced thrombosis factor that it maximally induces tissue factor after six to eight hours, and continues to induce tissue factor for up to sixty hours. This invention also provides purified nucleic acid molecules, antibodies, an inhibitor, an antagonist, pharmaceutical compositions, methods of treatment, and methods of preparation all directed to endotoxin-induced thrombosis factor. |
